CD40 agonists (193), PI3Kγ inhibitors (194), CD47 inhibitors (195), and a class IIa HDAC inhibitor (179) have all been shown to reduce primary and metastatic murine breast tumors (179) and have emerged as novel modalities to convert TAMs to anti-tumor macrophages. Here, CD47 is linked to neoplasm.